GATA2 was reported to function early in hematopoiesis 38 and was lowly expressed in several tumors, such as hepatocellular carcinoma 39, gastric cancer 40, clear cell renal cell carcinoma 35, and highly expressed in prostate cancer 41. Here, GATA2 is linked to prostate cancer.